Drug research: marketing before evidence, sales before safety
- PMID: 20467552
- PMCID: PMC2868983
- DOI: 10.3238/arztebl.2010.0277
Drug research: marketing before evidence, sales before safety
Comment on
-
The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.Dtsch Arztebl Int. 2010 Apr;107(16):279-85. doi: 10.3238/arztebl.2010.0279. Epub 2010 Apr 23. Dtsch Arztebl Int. 2010. PMID: 20467553 Free PMC article.
Similar articles
-
Reporting bias in industry-supported medication trials presented at the American Psychiatric Association meeting.J Clin Psychopharmacol. 2012 Jun;32(3):435. doi: 10.1097/JCP.0b013e318253d737. J Clin Psychopharmacol. 2012. PMID: 22561482 Free PMC article. No abstract available.
-
The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.Dtsch Arztebl Int. 2010 Apr;107(16):279-85. doi: 10.3238/arztebl.2010.0279. Epub 2010 Apr 23. Dtsch Arztebl Int. 2010. PMID: 20467553 Free PMC article.
-
Comments on cost analysis of risperidone versus olanzapine.J Clin Psychiatry. 2004 Jun;65(6):879-80; author reply 880. doi: 10.4088/jcp.v65n0622c. J Clin Psychiatry. 2004. PMID: 15291670 No abstract available.
-
Yes, industry influence is excessive.Int Psychogeriatr. 2007 Dec;19(6):1004-10; discussion 1014-20. doi: 10.1017/S1041610207006217. Epub 2007 Aug 22. Int Psychogeriatr. 2007. PMID: 17711608 No abstract available.
-
The impact of selective publication on clinical research in pain.Pain. 2008 Dec;140(3):401-404. doi: 10.1016/j.pain.2008.10.026. Epub 2008 Nov 11. Pain. 2008. PMID: 19004556 Review. No abstract available.
Cited by
-
Commentary: Reconsidering Pharmaceutical Research and Development Investments.Healthc Policy. 2023 Feb;18(3):25-30. doi: 10.12927/hcpol.2023.27037. Healthc Policy. 2023. PMID: 36917451 Free PMC article.
-
Reconsidering evidence-based management of endometriosis.Facts Views Vis Obgyn. 2022 Sep;14(3):225-233. doi: 10.52054/FVVO.14.3.033. Facts Views Vis Obgyn. 2022. PMID: 36206797 Free PMC article.
-
[From the design of use study to the assessment of the benefit: with or without pharmaceutical industry?].Med Klin (Munich). 2010 Dec;105(12):930-5. doi: 10.1007/s00063-010-1159-7. Epub 2011 Jan 16. Med Klin (Munich). 2010. PMID: 21240593 German.
-
Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.J Addict Res Ther. 2012 Nov 27;3(5):139. doi: 10.4172/2155-6105.1000139. J Addict Res Ther. 2012. PMID: 23926462 Free PMC article.
References
-
- Heres S, Davis J, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163(2):185–194. - PubMed
-
- Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig W-D, Lieb K. The financing of drug trials by pharmaceutical companies and its consequences: part 1. A qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials [Finanzierung von Arzneimittelstudien durch pharmazeutische Unternehmen und die Folgen - Teil 1: Qualitative systematische Literaturübersicht zum Einfluss auf Studienergebnisse, -protokoll und -qualität.] Dtsch Arztebl Int. 2010;107(16):279–285. - PMC - PubMed
-
- Bekelman J E, Li Y, et al. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289(4):454–465. - PubMed
-
- Topol EJ. Failing the public health—Rofecoxib, Merck, and the FDA. N Engl J Med. 2004;351(17):1707–1709. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical